Meeting & Congress

The Bioproduction Congress is the annual event of the biopharmaceutical production sector where stakeholders from Europe gather together to showcase and exchange the latest innovations in bioprocessing. This dynamic event promotes exchanges on the future of biomanufacturing, addresses the current challenges, and showcases new breakthrough solutions.

This event will bring together experts from companies (big pharmas, SME and Startups) and laboratories developing therapeutic candidates as well as leading bioproduction professionals to accelerate therapeutics drugs such as mAbs, vaccines, cell therapy and novel products into commercial manufacturing.

This meeting will focus on the recent expansion of scientific data and the current applications of next-generation sequencing technologies for adventitious virus detection in biological products.
This will include presentations on standardization and validation of the technical and bioinformatics steps involved in the NGS workflow and
applications of different NGS strategies for characterization and safety evaluation of biologics, including human and animal
vaccines, as well as gene therapy, and therapeutic products. Current regulatory expectations will be discussed.

The long-standing commercial CAR-T players must unite with the hottest trailblazing industry pioneers to shape and secure the future of cell therapy.
The 7th CAR-TCR Summit returns to Boston in 2022 in person with one goal: to engineer a disease-free world.
Across 4 days of carefully curated sessions, we will gather with 200+ CAR and TCR cell therapy VIPs that will lead you and your peers in discussions about novel allogeneic
approaches with enhanced safety considerations, the latest in vivo gene engineering techniques, and advances in CMC strategies and analytical development to ensure the development of high-quality cell products.

High-throughput sequencing (HTSeq) is of high interest to biopharmaceutical
manufacturers as seen from recent survey results indicating that 81% of CAACB member companies are
currently using or exploring the use of HTSeq for viral safety and the remaining 19% expect to do so in the
future. Despite this significant interest, practical experience in the implementation of HTSeq is not widely
available. To address this gap, we are looking for presentations and case studies sharing practical experiences
with implementing HTSeq for a range of applications.

Changing landscape of viral safet for existing and advanced technologies is a common target for the industry.
The overall program is designed to provide an update on regulatory expectations and the scientific framework around the virus safety of plasma-derived and biotechnology medicinal products, as well as particularly innovative cell- and gene therapies.

Access Today’s Innovative Scientific Data, Technologies, and Collaborations to Improve Efficiencies and Ensure Quality Across All Phases of Bioprocessing.

PathoQuest participates in the Next-Generation CAR-TCR European Event, a unique opportunity to connect with our team and understand how NGS could benefit your advanced therapies production.

PathoQuest participates in the Virtual Vaccines Congress Europe, a unique opportunity to connect with a large audience and demonstrate NGS benefits for the vaccine industry.

Industrial applications of NGS for viral safety and genetic characterization of biologics. Retrospective of the 2nd annual edition of PathoQuest NGS Workshop held in Paris, France the 18th of June 2019.